Completed PHASE1 INTERVENTIONAL NCT00001830

Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants

Pilot Study of Donor Th2 Cells for the Prevention of Graft-Versus-Host Disease in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation

Sponsor: National Cancer Institute (NCI)

Conditions Chronic Lymphocytic Leukemia Graft vs Host Disease Hodgkin's Disease Multiple Myeloma Non Hodgkin's Lymphoma

Interventions Th2 Cells Th2 cells in allo HSCTT

Updated 7 times since 2017 Last updated: Jul 3, 2018 Started: Jul 20, 1999 Completion: May 19, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Chronic Lymphocytic Leukemia and Graft vs Host Disease and is currently completed. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Aug 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States